Eli Lilly and Company revealed plans to expand its global research and development (R&D) headquarters in Indianapolis, Indiana. Adding 130,000 square feet to Lilly's existing complex, the new $70 million
building will feature a multi-disciplinary laboratory that facilitates
collaboration across multiple research functions. The new building is
part of Lilly's continued growth of its Indianapolis footprint, which included a $400 million expansion initiated in 2013 to increase its insulin manufacturing capacity.
Upon completion in 2017, the new building will enable organic chemists
and engineers to work side-by-side in a collaboration-centric workspace
with modelling, analytical and formulation scientists. Key to this
success will be flexible laboratories that can adapt as research and
technology needs evolve, as well as open, interactive meeting spaces
that are meant to spark creativity and multi-disciplinary
problem-solving. The laboratory will focus its efforts on small
molecules - treatments typically taken orally - which currently comprise
about half of Lilly's investigational medicines portfolio.
